Click here for slides on this topic


PPAR

Abbreviation for peroxisome proliferator-activated receptor. PPAR is a nuclear protein receptor that, when activated and linked to a co-activator protein, binds to DNA and acts to regulate transcription of a large number of genes, including some genes involved in adipose tissue, lipid and glucose metabolism. The antidiabetic drugs known as thiazolidinediones have been shown to bind to and activate PPAR. There are three known subtypes of PPARs-PPAR-alpha, PPAR-gamma, and PPAR-delta. Also referred to as PPAR ligand.
The following content matched the glossary term: PPAR

Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: acute effect of fatty acids

Top

Hoeks J, Hesselink MK, Russell AP, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: acute effect of fatty acids. Diabetologia. 2006;49:2419-2426. Peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1 (PPARGC1), a coactivator regulating the transcription of genes involved in oxidative metabolism, is downregulated in patients with type 2 diabetes and in their first-degree relatives.

Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes

Top

Blaschke F, Caglayan E, Hsueh WA. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Endocrinol Metabl Clin North Am. 2006;35:561-574. Thiazolidinediones (TZDs) a class of insulin sensitizing agents commonly used in the treatment of patients who have type 2 diabetes, improve endothelial dysfunction and exert beneficial effects on lipid profiles by activating the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-gamma).

PPAR-gamma Agonists and Diabetic Nephropathy

Top

Zhang Y, Guan Y. PPAR-gamma Agonists and Diabetic Nephropathy. Curr Diab Rep. 2005;5:470-475. Diabetic nephropathy is a clinical syndrome of albuminuria, declining glomerular filtration rate, and increased risk of cardiovascular disease.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study

Top

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289. Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes.

PPAR Ligands: Potential Therapies for Metabolic Syndrome

Top

Akiyama TE, Meinke PT, Berger JP. PPAR Ligands: Potential Therapies for Metabolic Syndrome. Curr Diab Rep. 2005;5:45-52. Metabolic syndrome (MS), a condition characterized by multiple related clinical disorders including insulin resistance, central obesity, hyperlipidemia, hypertension, and heart disease, is an increasingly prevalent disease in industrialized societies.

Evidence for a potent antiinflammatory effect of rosiglitazone

Top

Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89:2728-2735. We have recently demonstrated a potent antiinflammatory effect of troglitazone, an agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) and a partial agonist of PPAR-alpha in both the nondiabetic obese and diabetic obese subjects.

Peroxisome Proliferator-Activated Receptor-Gamma: Therapeutic Target for Diseases Beyond Diabetes: Quo Vadis?

Top

Pershadsingh, H. A.. Peroxisome Proliferator-Activated Receptor-Gamma: Therapeutic Target for Diseases Beyond Diabetes: Quo Vadis?. Expert Opin Investig Drugs. 2004;13:215-228. The discovery that the insulin-sensitising thiazolidinediones (TZDs), specific peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists, have antiproliferative, anti-inflammatory and immunomodulatory effects has led to the evaluation of their potential use in the treatment of diabetic complications and inflammatory, proliferative diseases in non-insulin-resistant, euglycaemic individuals.

Peroxisome Proliferator-Activated Receptor-g Ligands Inhibit TGF-ß1-Induced Fibronectin Expression in Glomerular Mesangial Cells

Top

Guo B, Koya D, Isona M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome Proliferator-Activated Receptor-g Ligands Inhibit TGF-ß1-Induced Fibronectin Expression in Glomerular Mesangial Cells. Diabetes. 2004;53:200-208. are ligands for peroxisome proliferator-activated receptor (PPAR)-g, has been shown to possess potent anti-inflammatory and antineoplastic actions.

Induction of Adiponectin, a Fat-Derived Antidiabetic and Antiatherogenic Factor, by Nuclear Receptors

Top

Iwaki M, Matsuda M, Maeda N, et al. Induction of Adiponectin, a Fat-Derived Antidiabetic and Antiatherogenic Factor, by Nuclear Receptors. Diabetes. 2003;52:1655-1663. Adiponectin is a fat-derived hormone with antidiabetic and antiatherogenic properties. Hypoadiponectinemia seen in obesity is associated with insulin-resistant diabetes and atherosclerosis.

Peroxisome Proliferator–Activated Receptor-a Agonist Treatment in Transgenic Model of Type 2 Diabetes Reverses Lipotoxic State & Improves Glucose Homeostasis

Top

Kim H, Haluzik M, Asghar Z, et al. Peroxisome Proliferator-Activated Receptor-alpha Agonist Treatment in a Transgenic Model of Type 2 Diabetes Reverses the Lipotoxic State and Improves Glucose Homeostasis. Diabetes. 2003;52:1770-1778. Abnormalities in insulin action are the characteristics of type 2 diabetes. Dominant-negative muscle-specific IGF-I receptor (MKR) mice exhibit elevated lipid levels at an early age and eventually develop type 2 diabetes.

1 2 Next 

Slide Library Results

Search Results for: PPAR Slides Found: 7
PPARg Ligand May Prevent Loss of B-Cell Mass
PPARs and Peroxisomes (animated)
Metabolic and Vascular Actions of PPAR-alpha and PPAR-gamma Agonists
AleCardio: Time to First Occurrence of Any Part of the Composite of CV Mortality, Nonfatal MI, or Nonfatal Stroke With Aleglitazar Vs Placebo
AleCardio: Aleglitazar Safety Vs Placebo
AleCardio: Design
Connection Between Type 2 Diabetes and Heart Failure PPT | NDEI